Prevalence of PSC-PBC Overlap Syndrome
PSC-PBC overlap syndrome is extremely rare and has been reported only in small case series, with no established prevalence data available. 1
Key Evidence from Guidelines
The 2019 British Society of Gastroenterology guidelines explicitly state that "A PSC/PBC overlap syndrome has been reported in only small case series" 1. This represents the highest quality guideline evidence available and indicates this is an exceptionally uncommon entity.
Why This Overlap is So Rare
The rarity may reflect diagnostic difficulty, particularly in patients with small duct PSC where:
- Classic cholangiographic features are absent
- Liver biopsy is often not diagnostic
- AMAs (antimitochondrial antibodies, the hallmark of PBC) are positive in <5% of PSC cases 1
Supporting Research Evidence
Recent case reports and small series confirm the extreme rarity:
- A 2026 Chilean hospital review found only 8 patients with PSC-PBC overlap over a 2-year period 2
- A 2023 case report series describes it as "extremely rare" with only "few published cases" 3
- A 2015 review noted only 6 published cases at that time 4
- A 2018 case report emphasizes "the cause for the rarity of this entity compared to other overlap syndromes is unclear" 5
Contrast with Other Overlap Syndromes
For context, PSC-AIH overlap is far more common:
- 7-14% of PSC patients meet criteria for AIH overlap in adults 6
- 1.4-17% overlap reported in various adult PSC cohorts 1
- Up to 52% in pediatric PSC populations 6
Clinical Implications
When to suspect PSC-PBC overlap:
- Patient with established PBC develops cholangiographic changes on MRCP
- Patient with PSC has positive AMA (though this occurs in <5% of PSC cases)
- Cholestatic biochemistry with features of both diseases
Important caveat: The true prevalence may be underestimated due to diagnostic challenges, particularly in small duct PSC where MRCP is normal and liver biopsy may not be definitive 1.